The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy

Journal of Urology

Volumn 185, Issue 1, 2011, Pages 54-59

  You, Dalsan ^a   Jeong, In Gab ^a   Ahn, Jin Hee ^a   Lee, Dae Ho ^a   Lee, Jae Lyun ^a   Hong, Jun Hyuk ^a   Ahn, Hanjong ^a   Kim, Choung Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Carcinoma, renal cell; Kidney; Mortality; Neoplasm metastasis; Nephrectomy

Indexed keywords

SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG DOSE REDUCTION; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOLECULARLY TARGETED THERAPY; MULTIVARIATE ANALYSIS; NEPHRECTOMY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; SARCOMA; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEPHRECTOMY; RETROSPECTIVE STUDIES;

EID: 78650020623     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.09.018     Document Type: Article

References (25)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225
2. B. Ljungberg, D.C. Hanbury, and M.A. Kuczyk Renal cell carcinoma guideline European Association of Urology Guideline Group for renal cell carcinoma Eur Urol 51 2007 1502
3. R.J. Motzer, M. Mazumdar, and J. Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530
4. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655
5. G.H. Mickisch, A. Garin, and H. van Poppel Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group Lancet 358 2001 966
6. R.C. Flanigan, G. Mickisch, and R. Sylvester Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 171 2004 1071
7. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115
8. B. Escudier, T. Eisen, W.M. Stadler TARGET Study Group Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125
9. B.I. Rini, and S.C. Campbell The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy J Urol 177 2007 1978
10. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228
11. R.J. Motzer, J. Bacik, and B.A. Murphy Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289
12. L. Zini, U. Capitanio, and P. Perrotte Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma Urology 73 2009 342
13. R.J. Motzer, R.M. Bukowski, and R.A. Figlin Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 2008 1552
14. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794
15. C. Szczylik, C. Porta, and S. Bracarda Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC) J Clin Oncol 26 suppl. 2008 abstract 5124
16. M. Warren, P.M. Venner, and S. North A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment Can Urol Assoc J 3 2009 281
17. Choueiri TK, Xie W, Kollmannsberger CK, et al. The impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy. Presented at American Society of Clinical Oncology Genitourinary Cancer Symposium, San Francisco, California, March 57, 2010.
18. J.R. Wagner, M.M. Walther, and W.M. Linehan Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place J Urol 162 1999 43
19. A. Bex, S. Horenblas, and W. Meinhardt The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ Eur Urol 42 2002 570
20. A.A. van derVeldt, M.R. Meijerink, and A.J. van denEertwegh Sunitinib for treatment of advanced renal cell cancer: primary tumor response Clin Cancer Res 14 2008 2431
21. C.G. Wood The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma Urol Clin North Am 30 2003 581
22. T. Klatte, M. Bhm, and T. Nelius Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma BJU Int 100 2007 209
23. A.L. Feldman, H.R. Alexander Jr, and J.C. Yang Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma Cancer 95 2002 1637
24. D.Y. Heng, and C. Kollmannsberger State-of-the-art treatment of metastatic renal cell carcinoma Curr Oncol 16 2009 S16
25. J. Barbastefano, J.A. Garcia, and P. Elson Association of percentage of tumor burden removed with debulking nephrectomy and progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients (Pts) treated with VEGF-targeted therapy J Clin Oncol 27 suppl. 2009 5095 abstract